At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MTVA MetaVia Inc
Pre-Mkt 10-22 06:11:48 EDT
1.34
+0.05
+3.88%
盘前1.40
+0.06+4.48%
05:43 EDT
High1.37
Low1.29
Vol42.29K
Open1.29
D1 Closing1.29
Amplitude6.20%
Mkt Cap8.83M
Tradable Cap6.44M
Total Shares6.59M
T/O56.93K
T/O Rate0.88%
Tradable Shares4.81M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
MetaVia Grants Chief Medical Officer 53,000 Restricted Stock Units Under 2022 Equity Plan
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.